Business
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
— Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M — RESEARCH TRIANGLE PARK, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update. “We began 2026 with continued stro
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"image","alt":"BioCryst Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"BioCryst Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2oMvvMIKvjA9d_E4SRIeSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NA--/https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85","width":300,"height":117}},"lazy":false},{"type":"text","content":"— Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —","length":123,"tagName":"p"},{"type":"text","content":"— Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M —","length":130,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update.","length":210,"tagName":"p"},{"type":"text","content":"“We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline,” said Charlie Gayer, President and Chief Executive Officer of BioCryst. “ORLADEYO continues to grow because its differentiated oral profile and high level of attack control meet the needs of an increasing number of people living with hereditary angioedema. At the same time, we remain on track with enrollment in our navenibart and BCX17725 pipeline programs. We are also pleased to partner again with Neopharmed Gentili for European rights to navenibart. This progress underscores our strategy to focus on rare diseases where we have deep expertise, execute efficiently, and allocate capital thoughtfully to drive sustainable value for patients and shareholders.”","length":808,"tagName":"p"},{"type":"text","content":"Business & Corporate Updates","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"New patient prescriptions in Q1 2026 continued to be strong, driving ORLADEYO revenue of $148.3 million (+11% y-o-y; +21% y-o-y on a comparable basis excluding European revenue).","length":178,"tagName":"p"}]},{"...